324 F.3d 518 (7th Cir. 2003), 02-3446, Ziliak v. AstraZeneca LP
|Citation:||324 F.3d 518|
|Party Name:||KATHLEEN ZILIAK, Plaintiff-Appellant v. ASTRAZENECA LP and ASTRAZENECA AB, Defendants-Appellees.|
|Case Date:||March 31, 2003|
|Court:||United States Courts of Appeals, Court of Appeals for the Seventh Circuit|
ARGUED FEBRUARY 28, 2003
Appeal from the United States District Court for the Southern District of Indiana, Evansville Division. No. 00 C 249. Richard L. Young, Judge.
C. Richard Martin (argued), Msrtin & Martin, Boonville, IN, for Plaintiff-Appellant.
Bonnie L. Gallivan, L.A. Whaley (argued), Ice Miller, Indianapolis, IN, for Defendant-Appellee.
Before POSNER, MANION, and ROVNER, Circuit Judges.
ROVNER, Circuit Judge.
Kathleen Ziliak suffers from bronchial asthma. To treat her disease, her physician, Dr. Frank Amodio, prescribed Pulmicort Turbuhaler ("Pulmicort"), an inhaled corticosteroid manufactured by AstraZeneca LP.1 Following clinical studies conducted in 1996 and 1997, AstraZeneca determined that on rare occasions Pulmicort users developed glaucoma, cataracts, and increased intraocular pressure. As a result, AstraZeneca issued package inserts warning that "rare instances of glaucoma, increased intraocular pressure, and cataracts have been reported following the inhaled administration of corticosteriods." Although he was aware of AstraZeneca's warnings and of the risks of using Pulmicort to treat asthma, Dr. Amodio decided to prescribe Pulmicort to Ziliak because, in his view, the benefits of using the drug outweighed the risks. Ziliak began using Pulmicort in January 1998. The following month, she informed to Dr. Amodio that she was "doing great" and had stopped coughing as a result of her asthma. In July, Ziliak saw Dr. Amodio again and reported that she had run out of Pulmicort and that she had started wheezing and having difficulty breathing again. Dr. Amodio decided that Ziliak should continue taking Pulmicort, and gave her a refill for her inhaler. Ziliak did not see Dr. Amodio again.
In November 1998, after a routine eye exam, Ziliak received the unfortunate news that she had developed severe glaucoma, cataracts, and high intraocular pressure. Following this diagnosis, Ziliak brought this products liability action against AstraZeneca in state court, alleging that AstraZeneca had failed to adequately warn of the risks of developing glaucoma, cataracts, and high intraocular pressure after using Pulmicort, and that the lack of adequate warnings rendered Pulmicort a defective or...
To continue readingFREE SIGN UP